Literature DB >> 23210896

Current therapeutic approaches of psoriasis are affected by age at disease onset.

Vito Di Lernia1, Elena Ficarelli.   

Abstract

Psoriasis in patients with early onset follows an irregular course with tendency to become severe and extensive. The aim of this study was to look for an association between age at onset of psoriasis and use of biologic agents for its treatment. We reviewed the medical records of 350 patients with moderate to severe psoriasis treated with systemic therapies and compared differences in age at disease onset between patients who had received biologics and those who had not. The mean age of our patients was 54.9 ± 15.1 years; 100 of them (28.6%) were currently receiving or had previously received treatment with a biologic agent. For those with biologic use, average age at the time of diagnosis of psoriasis was 28.2 ± 14.7 years, compared with 40.4 ± 18.1 years for those who had not received biologics. A total of 139 patients had psoriasis diagnosed before or at age 30 years. Sixty out of them (43.1%) had used biologics. Forty-four patients had psoriasis diagnosed after age 60 years, but only three out of them (6.8%) had used biologics. Concomitant arthritis was significantly associated with use of biologics. In our patients with psoriasis disease, frequency of treatment with a biologic agent varied inversely with age at disease onset.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23210896     DOI: 10.3109/09546634.2012.755258

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  3 in total

1.  Effect of Age of Onset of Psoriasis on Clinical Outcomes with Systemic Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Authors:  Sanminder Singh; Robert E Kalb; Elke M G J de Jong; Neil H Shear; Mark Lebwohl; Wayne Langholff; Lori Hopkins; Bhaskar Srivastava; April W Armstrong
Journal:  Am J Clin Dermatol       Date:  2018-12       Impact factor: 7.403

Review 2.  Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.

Authors:  V Di Lernia; F Bardazzi
Journal:  Drug Des Devel Ther       Date:  2016-01-29       Impact factor: 4.162

3.  Accuracy and Reliability of Subjective Answer about Age of Onset in Psoriasis.

Authors:  Jae-Wook Jeon; Hyuck-Hoon Kwon; Seong-Jin Jo; Ji-Young Ahn; Mi-Youn Park; Jai-Il Youn
Journal:  Ann Dermatol       Date:  2017-12-26       Impact factor: 1.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.